里昂发表研究报告,对中资医药股最新评级及目标价如下: 股份│投资评级│目标价(港元) 相关内容国药(01099.HK)附属国药一致首季净利润3.89亿人民币 增长7.3%中生制药(01177.HK) +0.030 (+1.095%) 沽空 $1.65千万; 比率 15.061% │买入│14.17元石药(01093.HK) +0.080 (+1.227%) 沽空 $2.45千万; 比率 7.921% │买入│23.37元三生制药(01530.HK) +0.030 (+0.496%) 沽空 $1.15千万; 比率 18.746% │买入│17.43元复星医药(02196.HK) +0.260 (+2.167%) 沽空 $2.98百万; 比率 6.440% │跑输大市│23.53元翰森制药(03692.HK) +0.420 (+2.500%) 沽空 $1.09千万; 比率 11.506% │跑赢大市│30.77元中国同辐(01763.HK) +0.540 (+5.253%) │买入│26.78元百济神州(06160.HK) +1.950 (+2.167%) 沽空 $4.51千万; 比率 28.397% │买入│144.04元华领医药(02552.HK) +0.030 (+1.887%) │买入│10.34元药明生物(02269.HK) +0.740 (+5.808%) 沽空 $4.75千万; 比率 6.442% │买入│102.62->139.69元药明康德(02359.HK) +1.450 (+4.296%) 沽空 $1.14千万; 比率 3.587% │买入│115.63->142.37元方达控股(01521.HK) -0.020 (-1.538%) │跑赢大市->买入│5.97元康龙化成(03759.HK) +0.680 (+7.727%) 沽空 $1.76百万; 比率 2.649% │买入│53.69->68.25元国药(01099.HK) -0.200 (-0.920%) 沽空 $6.28千万; 比率 36.335% │买入│38.69元华润医药(03320.HK) +0.080 (+1.613%) 沽空 $2.14百万; 比率 4.265% │买入│14.21元上海医药(02607.HK) +0.100 (+0.891%) 沽空 $2.60百万; 比率 8.559% │买入│24.04元锦欣生殖(01951.HK) +0.140 (+5.691%) 沽空 $7.74百万; 比率 11.369% │跑赢大市->买入│15.37元 (sw/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-26 16:25。)